Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 126

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 126
---
 recurring fair value measurement, we expect that we will recognize non-cash gains or losses on our Earnout Shares each reporting period and that the amount of such gains or losses could materially impact or cause volatility in our financial results. 68 USE OF PROCEEDS We estimate that we will receive net proceeds of approximately $6.9 million, after deducting the placement agent fees and estimated offering expenses payable by us (based on an assumed public offering price of $2.00 per share, which was the last reported sales price of our Common Stock on the Nasdaq Global Market on February 3, 2025) and assuming no sale of any Pre-Funded Warrants and no exercise of Offered Common Warrants. However, because this is a best efforts offering with no minimum number of securities or amount of proceeds as a condition to closing, the actual offering amount, placement agent fees and net proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth on the cover page of this prospectus, and we may not sell all or any of the securities we are offering. As a result, we may receive significantly less in net proceeds. Based on the assumed offering price set forth above, we estimate that our net proceeds from the sale of 75%, 50% or 25% of the securities offered in this offering would be approximately $5.0 million, $3.2 million and $1.4 million, respectively, after deducting placement agent fees and estimated offering expenses payable by us. We currently intend to use the net proceeds from this offering, together with our existing cash resources, toward the following activities in their order of importance:

| ● | advancement of our clinical programs; and |

| ● | fund working capital and other general                                                                                            
 corporate purposes, which may include the redemption of shares of our outstanding Series A, Series B or Series C Preferred Stock. |

This expected use of net proceeds from this offering represents our intentions based upon our current plans and business conditions. We have not determined the exact amounts we may spend on any of the items listed above or the timing of these expenditures. Our management will retain broad discretion over the allocation of the net proceeds from this offering. We may find it necessary or advisable to use the net proceeds from this offering for other purposes, and we will have broad discretion in the application of net proceeds. Although we may use a portion of the net proceeds of this offering for the acquisition or licensing, as the case may be, of additional technologies, other assets or